Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

40.02 +0.55 (+1.39%)
Streaming Delayed Price Updated: 12:08 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V.

< Previous 1 2 3 4 5 6 Next >
Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends
Qiagen NV's (NASDAQ: QGEN) Q3 net sales of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the  
Via Benzinga
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday. 
Via Benzinga
Exposures COVID-19
Will Chart Analysts Notice Bad Omen on Qiagen's Chart
Via Benzinga
Earnings Scheduled For February 6, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion. 
Via Benzinga
Earnings Preview: Qiagen
Via Benzinga
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion
Goldman Sachs upgrades Twist Bioscience as Express Genes launch addresses SynBio division's gross margin issues. With 5-7 days gene delivery, TWST taps into a previously inaccessible market, enhancing... 
Via Benzinga
Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects
QIAGEN N.V. (NYSE: QGEN) disclosed its expansion plan in  
Via Benzinga
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock
Qiagen NV (NYSE: QGEN) has a steady income from selling tools for preparing samples and diagnostics. 
Via Benzinga
Where Qiagen Stands With Analysts
Via Benzinga
These Companies Helped The German DAX Index Hit Its All-time High
The DAX 40 index surged to its all-time high on Tuesday, continuing the remarkable rally that started on October 23rd. The index, which tracks the 40 biggest companies in Germany, soared to a high of... 
Via Talk Markets
Analyst Expectations for Qiagen's Future
Via Benzinga
Preview: Qiagen's Earnings
Via Benzinga
Earnings Scheduled For October 30, 2023
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is likely to report earnings for its third quarter. 
Via Benzinga
Analyst Expectations for Qiagen's Future
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
The 3 Most Promising Biotech Stocks to Buy Now
With the NIH requesting its biggest budget yet, these are the three most promising healthcare stocks to buy now. 
Via InvestorPlace
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
From QIAGEN N.V.
Via Business Wire
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation Sequencing
From QIAGEN N.V.
Via Business Wire
QIAGEN’s tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR framework
From QIAGEN N.V.
Via Business Wire
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product Groups
From QIAGEN N.V.
Via Business Wire
Genetic Technologies Shares Jump After Strategic Alliance With Qiagen
Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia. 
Via Benzinga
QIAGEN Launches EZ2 Connect MDx Platform for Automated Sample Processing in Diagnostic Labs
From QIAGEN N.V.
Via Business Wire
QIAGEN N.V. to Release Results for Q4 and Full-Year Results 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
Bloomberg 
Via Benzinga
QIAGEN Acquires Verogen Strengthening Its Position In Human ID / Forensics
Via Benzinga
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
From QIAGEN
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.